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Abstract: Tauopathies are a group of more than twenty known disorders that involve progressive neu-
rodegeneration, cognitive decline and pathological tau accumulation. Current therapeutic strategies
provide only limited, late-stage symptomatic treatment. This is partly due to lack of understanding
of the molecular mechanisms linking tau and cellular dysfunction, especially during the early stages
of disease progression. In this study, we treated early stage tau transgenic mice with a multi-target
kinase inhibitor to identify novel substrates that contribute to cognitive impairment and exhibit
therapeutic potential. Drug treatment significantly ameliorated brain atrophy and cognitive function
as determined by behavioral testing and a sensitive imaging technique called manganese-enhanced
magnetic resonance imaging (MEMRI) with quantitative R1 mapping. Surprisingly, these benefits
occurred despite unchanged hyperphosphorylated tau levels. To elucidate the mechanism behind
these improved cognitive outcomes, we performed quantitative proteomics to determine the altered
protein network during this early stage in tauopathy and compare this model with the human
Alzheimer’s disease (AD) proteome. We identified a cluster of preserved pathways shared with
human tauopathy with striking potential for broad multi-target kinase intervention. We further
report high confidence candidate proteins as novel therapeutically relevant targets for the treatment
of tauopathy. Proteomics data are available via ProteomeXchange with identifier PXD023562.
Keywords: tau; GSK2606414; kinases; MEMRI; TMT proteomics
1. Introduction
Tauopathies, the most common of which is Alzheimer’s disease (AD), are a group of
neurological disorders defined by the neuropathological accumulation of tau protein that
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present progressive cognitive dysfunction and brain atrophy. No cure for tauopathies exists
and current treatment strategies are palliative [1,2]. Several clinical trials have targeted toxic
tau species through immunotherapies or by inhibiting tau post-translational modifications
and fibrillization with mixed results [1–4]. However, the disease etiology of tauopathies,
AD in particular, are almost certainly multifactorial. A promising strategy to mitigate
the complex nature of tauopathies, similar to established approaches for other chronic,
progressive diseases, encompass multi-target or combinatorial treatments [3,5]. These
strategies are limited by requiring a thorough understanding of the cellular perturbations
that underly the disease.
Modern systems biology approaches provide unparalleled power in investigating the
cellular alterations in disease. These tools highlight promising candidate targets for novel
therapeutics while elucidating the pathophysiology of the disease. Recent studies focused
on the molecular network changes in AD suggest concurrent changes in energy metabolism,
immune response, synapse activity, cytoskeletal stability and RNA metabolism pathways
present early in disease progression [6–8]. These reports validate decades of research
utilizing in vitro and in vivo disease models. Using these tools, the pathways most closely
associated with early cognitive decline and neurodegeneration can be determined and
used to assess novel therapeutics. Importantly, these resources have not yet been applied to
establish the efficacy of multi-target drugs in mitigating cognitive decline in animal models
of tauopathy.
Aberrant phosphorylation and kinase signaling is a hallmark of AD and other
tauopathies [8,9]. Here, we report the use of a multi-target kinase inhibitor, GSK2606414 or
414, to treat tau transgenic mice in a proof-of-concept study to evaluate whether such strate-
gies can mitigate the early negative outcomes of tauopathy. This compound potently in-
hibits multiple tyrosine and serine/threonine kinases at low micromolar concentrations [10]
and ameliorates phenotypes in a variety of neurological disorder and neurodegenerative
models [11–16]. The targets of 414 include kinases involved in tauopathy pathogenesis, in-
cluding protein kinase R-like endoplasmic reticulum kinase or PERK [10–12], the mitogen-
activated protein kinase, or MAPK, cascade [10], receptor-interacting serine/threonine-
protein kinase 1 or RIPK1 [17] and the receptor tyrosine kinase, KIT [18]. We show that
brain atrophy and phenotypes of cognitive dysfunction evident in this mouse model of
tauopathy are substantially reduced by treatment with 414. Using manganese-enhanced
MRI (MEMRI) with parametric mapping, we show that multi-target kinase inhibition
rescues deficits in hippocampal calcium activity. The rescue of tauopathy occurs in the
absence of changes to toxic, hyper-phosphorylated tau levels and without inhibition of
PERK, the target canonically associated with the neuroprotective benefits of 414 [10,11]. We
used quantitative proteomics to investigate both the cellular alterations and the networks
responsive to multi-target kinase inhibition associated with cognitive rescue in this early
stage tauopathic mouse model. Finally, we identify novel candidate proteins that are
rescued by drug treatment and are consistent between the tauopathy mouse and human
proteome. These analyses identify novel candidate targets for therapeutic intervention in
future studies.
2. Results
2.1. Tau Transgenic Mice Exhibit Common Neurodegenerative Features Ameliorated by
Multi-Target Kinase Inhibition
To investigate the pathways responsible for early cognitive impairment in tauopathy
and their amenability to treatment with a multi-target kinase inhibitor, we used the rTg4510
tau transgenic mouse model of frontotemporal lobar degeneration (FTLD). The rTg4510
(Tg) mice exhibit well-characterized disease progression driven by the overexpression of
P301L human tau primarily in forebrain neurons [19–21]. Neurofibrillary tau pathology
appears as early as two months, with progressively worsening cognitive impairment
detectable as early as two and a half months. Additionally, significant brain atrophy is
detectable in this model by 5 months of age (Figure 1A).
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Figure 1. Multi-target kinase inhibition with GSK2606414 rescues brain atrophy in rTg4510 tau
transgenic mice. (A) Timeline of tauopathy phenotype in transgenic (Tg) mice and depiction of drug
delivery between 4–5mo. (B–E) Representative T2-weighted MR images of non-transgenic (NTg) and
Tg mice treated with vehicle (Veh) or GSK2606414 (414). (F) Total brain volume quantification (NTg +
414, n = 2; others n = 3). Two-way ANOVA with Tukey post hoc test. Data are expressed as the mean
± SEM, ** p < 0.01. ns: not significant.
We treated four-month-old Tg and non-transgenic control (NTg) mice with the multi-
target kinase inhibitor GSK2606414 (414) for 30 days. Four-month-old Tg mice display
significant tau burden but they do not present with severe cognitive impairment and therefore
provide a therapeutic window amenable to treatment strategies. T2-weighted magnetic
resonance imaging (MRI) (Figure 1B–F) revealed that Tg mice treated with vehicle (Tg +
Veh) exhibited an approximately 20% reduction in total brain volume compared with non-
transgenic control mice treated with vehicle (NTg + Veh, ** p = 0.0063). Surprisingly, tau
transgenic mice treated with 414 (Tg + 414) exhibited only a 10% reduction in total brain
volume that lacked statistical significance from NTg + Veh control animals (ns, p > 0.15).
We previously established that this tau transgenic mouse line exhibits altered calcium
homeostasis detected by MEMRI with R1 relaxation mapping as early as 3mo of age which
continues as the mice age [22]. Here, we corroborated those findings, identifying altered
∆R1 in 5mo Tg mice (Figure 2A–D). The strongest differences in ∆R1 observed were found
in hippocampal regions such as the dentate gyrus (DG, Figure 2E) and Cornu ammonis area
1 (CA1, Figure 2F). In both regions, our experimental Tg + Veh mice exhibited significantly
decreased ∆R1 when compared to the control NTg + Veh mice (DG, *** p = 0.0003; CA1,
* p = 0.0226). Tg + 414 treated mice displayed no apparent impairment in calcium activity
measured by MEMRI in both regions relative to NTg + Veh mice (DG and CA1, ns) and
displayed significant improvement in calcium activity relative to the Tg + Veh animals
(DG, ** p = 0.0019; CA1, * p = 0.0211). These findings demonstrate that, in tandem with the
changes in total brain volume, treatment with the multi-target kinase inhibitor 414 rescued
hippocampal activity deficits in this model.
Since calcium dyshomeostasis underlies cognitive impairments in tauopathy [23],
we evaluated the effects of 414 in two behavioral paradigms—open field as a measure of
anxiety-like phenotype and Y-maze as a measure of cognition. The open field behavioral
paradigm demonstrated a Tg phenotype wherein Tg + Veh mice spent more time in the
field periphery than either NTg group (NTg + Veh: ** p = 0.0012; NTg + 414: *** p = 0.0001),
suggesting a transgene-dependent anxiety-like behavior (Figure 2G). Tg mice treated with
414 spent significantly less time in the periphery than Veh treated Tg mice (* p = 0.0260)
and were statistically indistinguishable from either NTg treatment group (ns, p > 0.15). In
the Y-maze, Tg + Veh mice exhibited decreased novel arm entries (* p = 0.0365) compared to
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NTg control mice. Treatment of Tg animals with 414, though statistically indistinguishable
from the NTg groups (ns, p > 0.15), only partially rescued the number of entries (ns,
p = 0.1095) compared to vehicle-treated Tg mice (Figure 2H). Total time spent in the novel
arm indicated Tg + Veh mice had reduced performance compared to NTg + Veh mice
(* p = 0.0433). Again, the Tg + 414 treatment group was statistically indistinguishable from
either NTg group (ns, p > 0.15) but displayed an incomplete rescue of this phenotype as
compared to Tg + Veh mice (ns, p = 0.0882) (Figure S1). Consistent with our MEMRI and
brain volume data, these data demonstrated that treatment with 414 mitigates the cognitive
deficits of early-stage tauopathy in this model.
Figure 2. GSK2606414 treatment rescues brain dysfunction in tau transgenic mice. (A–D) Representa-
tive ∆R1-rendered manganese-enhanced MRI (MEMRI) images. The insets in panels A-D show half
of the hippocampus of each representative image. (E,F) Calculated ∆R1 values in the dentate gyrus
(DG, (E)) and Cannu ammonis 1 (CA1, (F)). Two-way ANOVA with Tukey post hoc test. Data are
expressed as the mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001, (n = 4–5). (G) Results of open field
behavioral task indicating percent of time spent in the periphery, normalized to the first five minutes
(n = 6–10). Two-way ANOVA with Tukey post hoc test. Data are expressed as the mean relative to
NTg + Veh ± SEM, * p < 0.05. (H) Y-maze behavioral task results for number of novel arm entries
(n = 5–7). Two-way ANOVA with Tukey post hoc test. Data expressed as the mean ± SEM, * p < 0.05,
& denotes p = 0.1095.
2.2. GSK2606414 Rescues Functional Deficits without Altering Tau Hyper-Phosphorylation
A previous study reported that GSK2606414 reduced tau pathology by preventing
PERK activation and consequent enhancement of GSK3β activity [11]. GSK3β phospho-
rylates tau at sites that are associated with tauopathy progression [24]. To test whether
decreased tau phosphorylation was responsible for the cognitive rescue in Tg mice, we
measured the levels of disease-associated, hyper-phosphorylated tau at the S396/S404
(PHF1) and total tau levels (Figure 3A). 414 did not modify the levels of PHF1, total tau or
the relative phosphorylation at the PHF1 epitope (Figure 3B–D).
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Figure 3. GSK2606414-mediated cognitive rescue in early-stage tau transgenic mice is independent of
tau hyper-phosphorylation. (A) Immunoblots of PHF1 (S396/S414) and total tau in 5mo NTg and Tg
animals treated with vehicle or GSK2606414 (414). (B–D) Results of PHF1 (B), total tau (C) and relative
phosphorylation (D) is normalized to GAPDH (n = 3). Two-way ANOVA with Tukey post hoc test.
Data are expressed as the mean relative to Tg + Veh ± SEM. ns: not significant. (E–H) Representative
images of active, pT980 PERK (pPERK) staining. All images were post-processed equally and
highlights lack of positive staining in 5mo Tg mice. Scale bar = 25 microns. (I) Quantification of
pPERK staining reveals that 414 treatment has no detectable change in 5mo Tg mice (n = 5–7) but
strongly inhibits PERK activity in the CA3 and superior medial cortex (Ctx) in 8mo Tg mice (hatched
bars, n = 3). Two-way ANOVA with Sidak post hoc test. Data are expressed as the mean relative to
NTg + Veh ± SEM, **** p < 0.0001. ns: not significant. (J) Relative hippocampal gene expression of
direct mediators of the PERK-UPR pathway in 5mo NTg and Tg mice treated for 30 d with Veh or
414 normalized to GAPDH and 18 S (n = 4–6). Two-way ANOVA with Tukey post hoc test. Data are
expressed as the mean relative to NTg + Veh ± SEM, * p < 0.05, ** p < 0.01. (K,L) Representative
images (K) and quantification (L) of overlap between NRF2 (red) and nuclear staining (DAPI, blue)
in the CA3 of 5mo NTg and Tg mice treated with either Veh or 414 (n = 3). Unpaired Student’s t-test.
Error bars denote SEM. Scale bar = 25 microns.
2.3. Functional Deficits of Early Stage Tau Transgenic Mice Do Not Depend on
PERK/UPR Activation
GSK2606414 was developed as a first-in-class inhibitor of PERK [10]. PERK, an en-
doplasmic reticulum (ER)-associated kinase, functions as part of the unfolded protein
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response (UPR) by attenuating global translation and dampening the level of incoming
nascent proteins in the ER under conditions of ER stress [25]. However, long term PERK
activation leads to sustained suppression of translation and activation of pro-apoptotic
signaling cascades. Previous studies have used 414 to inhibit PERK to prevent neurodegen-
eration by limiting the deleterious chronic activation of the (UPR) [11,12,25]. We evaluated
whether this PERK activity was responsible for neurodegeneration in early stage Tg mice.
Consistent with previous reports [11,26,27], PERK activation (as measured by the phospho-
rylation of T980) was minimally detected by immunofluorescent stains of the hippocampus
and cortex of 5mo Tg mice (Figure 3E–H). At 8mo, Tg mice had over one hundred-fold
greater levels of phosphorylated PERK (Figure 3I,J) which was inhibited by 414 treatment
as previously reported (Figure 3I) [11]. Quantitative real-time PCR gene card arrays ver-
ified our immunofluorescence results by demonstrating that expression levels of genes
downstream of PERK were largely unchanged in the 5mo Tg animals compared to NTg
controls and were unmodified by 414 (Figure 3J). We measured other mediators of the
UPR distinct from the PERK such as ATF6, IRE1 and other eIF2α kinases. Only the tran-
scriptional regulator ATF6 exhibited a significant change in transcript levels in Tg mice,
with a reduction of ATF6 mRNA levels in Tg + Veh mice and 414 treated mice (Figure S2).
PERK reportedly switches preferential substrate phosphorylation in tauopathies between
eIF2α and NRF2, a transcription that promotes expression of redox response proteins [28].
414 treatment did not alter NRF2 nuclear translocation in Tg model mice (Figure 3K,L).
Considering the off-target effects of kinase inhibitors and those targeted by 414 beyond
PERK at nanomolar and low micromolar concentrations (Table S1), we reasoned that the
neuroprotective effect of 414 is likely due to a multi-target response distinct from inhibiting
PERK kinase activity.
2.4. Quantitative Hippocampal Proteomics Reveals Pathways Responsible for Cognitive Decline in
Early Stage Tauopathy Mice
To assess the effects of a compound impacting multiple cellular pathways simultane-
ously, we turned to quantitative proteomics to identify proteins and pathways impacted by
transgenicity and our test agent, 414. Despite the prevalence of the rTg4510 model in the
study of neurodegeneration, no quantitative analysis of the brain proteome in these mice
has been reported. To this end, we evaluated the hippocampal proteome of NTg and Tg
mice treated with either Veh or 414 (n = 4 per group, all female) using a multiplexed tandem
mass tagging (TMT) approach (Figure 4A). Following protein quantification, batch normal-
ization and statistical analyses, 337 proteins were identified as significantly altered across
all group comparisons (FDR adjusted p value < 0.05, Figure 4B). First, we identified the
impact of 414 treatment on proteins in NTg animals (termed: “Drug Effect”) and removed
these proteins from further analysis. Next, we determined which proteins were altered due
to Tg genotype (termed: “Tg Effect”) by comparing NTg + Veh vs. Tg + Veh samples and
specifically excluded any genes known to be dysregulated due to transgene insertion in
this model [29,30]. We then identified the proteins that were rescued by 414 treatment in
the Tg mice: proteins in the “Tg Effect” group that were restored to statistically normal
levels in Tg mice (no significant difference from NTg + Veh mice) following treatment
with 414 (termed: “Drug Rescued”). These groupings are summarized in (Figure 4C) and
representative proteins belonging to each group are shown in (Figure 4D). Interestingly,
≈67% of the proteins altered in Tg mice were rescued after treatment with 414 (186 out of
276). Importantly and as expected, the human MAPT P301L transgene was significantly
upregulated in Tg mice and unaffected by 414 (Figure 4E). Tau phosphorylation was further
assessed using immobilized metal affinity chromatography (IMAC) enrichment and subse-
quent LC-MS/MS for phospho-proteomic analysis. Phospho-proteomic analysis revealed
tau phosphorylation at 13 phospho-peptides uniquely mapping to human MAPT P301L
(FDR < 1%). Averaging the abundance of these phospho-peptides as a measure of overall
tau phosphorylation indicated no significant difference in tau phosphorylation in between
Tg 414 treated or untreated groups (Figure 4F and Figure S3). Together, these proteomic
data strengthen the claim that the neuroprotective benefits of 414 are independent of tau.
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Figure 4. Hippocampal proteome signatures of early stage tauopathy model mice. (A) Schematic of TMT isobaric tag
proteomic pipeline. Mice hippocampal sections were extracted and lysed. Individual isobaric tags were used to chemically
label proteins from each individual sample and combined for liquid chromatography/tandem mass spectrometry (LC/MS-
MS) detection. Batch normalization was completed using a shared batch correction standard, resulting in n = 4 per group.
All samples were from female mice. (B) Heatmap of proteomics results showing 337 significantly altered proteins across
all comparisons. (C) Summation of the number of significantly altered proteins across each test identified by proteomics.
(D) Representative protein for each test of significant differential abundance (FDR adjusted, * p < 0.05). (E) Protein abundance
of human MAPT P301L transgene (FDR adjusted, * p < 0.05). (F) Abundance of each human MAPT P301L phospho-peptide
detected by phospho-proteomics. (G,H) Network clustering of Reactome pathways found up-regulated (G) or down-
regulated (H) due to tau transgenic genotype relative to NTg mice (Tg effect). Node size proportionally represents the
protein count in that pathway, whereas node color represents the statistical significance gradient (FDR-adjusted p value)
from p = 0.10 (brown) approaching p = 0 (white). Dashed connections indicate manually adjusted nodes.
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Next, we analyzed the pathway level changes in the 5mo Tg brain proteome. To
collapse the altered protein into pathways, we used g.Profiler [31] to assess the changes in
Reactome [32] annotated pathways (FDR adjusted p value < 0.1, Table S2). Cytoscape [33]
was used to cluster each pathway into larger umbrella networks that were down-regulated
(Figure 4G) or up-regulated (Figure 4H) in Tg mice. The down-regulated protein net-
work clustered into nine discrete groups, namely: mTOR pathway activity, synaptic ac-
tivity and long-term potentiation, reactive oxygen species defense, calcium dynamics,
vesicle-mediated transport and endocytosis, rho GTPase activity, muscle contraction, RNA
metabolism and splicing, as well as aerobic respiration and mitochondrial activity. The
number of up-regulated protein networks was considerably larger despite having fewer
significantly altered proteins compared to down-regulated proteins. Up-regulated path-
ways clustered into the following groups: Golgi/ER transport, ion conductance, immune
response kinase activity, aerobic respiration and mitochondrial function, axonal and neu-
ritic morphogenesis, neurotransmitter release, amino acid metabolism, heat shock stress
response, insulin signaling, rho GTPase activity, cell cycle, Wnt and Hedgehog signaling,
as well as gap junctions and plasma membrane.
2.5. Multi-Target Kinase Inhibition via GSK2606414 Treatment Rescues Proteomic Shifts
in Tauopathy
Having identified and mapped the pathway changes in Tg mice, we sought to deter-
mine the pathways that were affected by 414 that associated with cognitive rescue. To that
end, we repeated clustering analysis of Reactome pathways (FDR adjusted p-value < 0.1)
representing “Drug Rescued” proteins that were either initially down-regulated (Figure 5A)
or up-regulated (Figure 5B) in Tg + Veh mice and rescued back toward NTg control levels
with 414 treatment. Pathway groups initially down-regulated in Tg + Veh mice and res-
cued up toward NTg control levels included: aerobic respiration, long-term potentiation,
muscle contraction, ion conductance and rho GTPase activity. Other pathways initially
up-regulated in Tg + Veh mice and restored to NTg control levels included: amino acid
metabolism, aerobic respiration and mitochondrial function, heat shock stress response,
Golgi-ER membrane trafficking, axonal and neuritic morphogenesis, apoptotic protein
degradation, cell cycle, gap junction and plasma membrane, immune response kinase
activity, ion conductance, N-methyl-D-aspartate (NMDA) post-synaptic activity, Wnt and
Hedgehog signaling and RNA metabolism and translation.
To validate these proteomic results, we focused on two distinct cellular processes
that were rescued by 414: RNA translation and mitochondrial redox defense. RNA trans-
lation was assessed by a novel metabolic labeling method developed to investigate the
translational dysregulation of tauopathy in vivo [27]. This method involved an intraperi-
toneal injection of puromycin, a tRNA analog, shortly before death to rapidly label nascent
polypeptide chains [34]. Anti-puromycin antibodies were then used to probe for proteins
that incorporated the puromycin as a direct measure of polypeptide elongation and RNA
translation. Anti-puromycin staining of the CA1 region revealed significantly increased
translation activity in Tg + 414 (* p < 0.05) compared to Tg + Veh mice (Figure 5C,D).
Secondly, since nitroxidative stress is a marker of mitochondrial dysregulation and it is
implicated in the pathogenesis of AD and other tauopathies [35,36], we measured changes
in protein nitration between our animal groups. Immunoblot results identified a significant
increase in protein nitration (3-NT) in Tg + Veh animals which was rescued with 414
treatment (Figure 5E,F). Together, these results validated the pathway level changes that
were rescued in Tg mice by treatment with 414.
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Figure 5. Multi-target kinase inhibition rescues pathways related to cognitive and neuronal function in early-stage tau
transgenic mice. (A,B) Network clustering of Reactome pathways found up-regulated (F) or down-regulated (G) in Tg
mice and significantly rescued toward NTg + Veh levels in Tg + 414 mice. Node size proportionally represents the protein
count in that pathway, whereas node color represents the statistical significance gradient (FDR-adjusted p value) from
p = 0.10 (brown) approaching p = 0 (white). Dashed connections indicate manually adjusted nodes. (C,D) Puromycin
immunostaining of the CA1 region (D) and quantified (E) relative to total CA1 area (n = 3). One-way ANOVA with
Tukey post hoc test. Data are expressed as the mean absolute integrated density ± SEM, * p < 0.05. Scale bar = 25 microns.
(E,F) Immunoblots (e) of total tyrosine nitration and total lane quantified results (F) relative to NTg + Veh and normalized
to actin (n = 3–4). Two-way ANOVA with Tukey post hoc test. Data are expressed as the mean relative to Tg + Veh ± SEM,
** p < 0.01.
2.6. Early Stage Tauopathy Exhibits Common Protein Alterations Targetable by Broad
Kinase Inhibition
Finally, we investigated how the Tg hippocampal proteome compared with human
tauopathy to provide a context for our findings in AD. We correlated the 276 proteins
altered by “Tg Effect” with two independent proteomic analyses of the human AD brain
to identify both model-specific alterations and novel candidate proteins (Table S3). The
majority of significantly altered mouse proteins mapped to human homologs (>90%) in
both human tauopathy datasets, as expected. First, to account for the disparity in pathology
between the tauopathy Tg mouse model and AD, we assessed the consistency of proteomic
alterations between Tg mouse and preclinical (or asymptomatic) AD and late-stage AD
samples (Figure 6A). Individuals with asymptomatic AD (Asym AD) included in this
analysis exhibited minimal cognitive impairment with moderate to high amyloid plaque
frequency but with low to no cortical tau pathology (Table S4) [37]. Late AD samples, how-
ever, had significant cognitive impairment and high degrees of amyloid and tau pathology.
By identifying the proteins consistent between Tg mice and Asym AD distinct from late AD,
we classified which proteins are considered early markers of AD- and tauopathy-specific
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progression, respectively. We found that 15 of 20 human homologs significantly altered
in Asym AD vs. healthy control brains were consistently altered in Tg animals (75%;
hypergeometric test, **** p < 0.0001). Of these 15, nine homolog proteins were rescued by
414 in Tg mice: NUCB1, SNCA, FKBP1A, PKM, YWHAZ, HSPE1, GRPEL1, NDUFB10 and
HOMER1. These nine proteins are implicated in other neurodegenerative diseases or cellu-
lar processes known to be dysregulated early in tauopathy pathogenesis such as synaptic
plasticity, proteostasis, glucose metabolism and mitochondrial function. Tg mice matched
to a greater extent with the late AD proteome, where 29 out of 47 significantly altered
proteins were inter-specially consistent (≈62%; hypergeometric test, ** p < 0.01). Of these
29 proteins, 23 homologs were rescued by 414 in Tg mice: NUCB1, NTM, ATOX1, SNCA,
ENO1, GJA1, FKBP1A, ATP6V1E1, PKM, STMN1, VSNL1, YWHAZ, HINT1, HPCA, PEPD,
ROGDI, PPP1R7, PACSIN1, HSPE1, RTN1, NDUFB5, DMTN and HOMER1. These pro-
teins function in pathways rescued by 414 in Tg mice, namely aerobic respiration/glucose
metabolism, mitochondrial function, endocytosis and trafficking, immune system activa-
tion, signaling cascades. Interestingly, several proteins were found consistent across disease
staging: NUCB1, SNCA, FKBP1A, PKM, YWHAZ, HSPE1, HOMER1. Since each of these
were rescued by 414 in Tg mice, they may be important candidate proteins to consider for
future studies.
Figure 6. Proteomic signatures of rTg4510 transgenic mice match human tauopathy and reveal novel candidates for
therapeutic intervention. (A,B) Significantly altered proteins by Tg effect were compared to human homolog abundances
found in two proteomics datasets of human neurodegenerative diseases ((A), [37]; (B), [38]). Proteins annotated in the
“Rescued” column (yellow) were significantly rescued by 414 in Tg animals compared to NTg controls. Human homolog
protein abundances in each disease group were compared to non-demented controls. Statistically altered human proteins
were annotated by disease group in different colors (Asym Alzheimer’s disease (AD), pink; late AD, purple; late PD, green).
Proteins that were significantly altered in the same direction (increased or decreased) between species and also represented
proteins rescued by 414 in Tg mice were annotated in the “Consistent” column (black). Candidate proteins passing all
criteria for inclusion were labeled with their corresponding human gene symbols. Sample abundances were averaged per
group and each corresponding sample number was appended to the bottom of each column. (C) Venn diagram comparing
candidate proteins identified in late AD across both datasets.
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Considering that the proteome in late-stage neurodegenerative diseases may relate
more to widespread brain organ failure and may not be a specific response to any one
disease [39], we investigated how the Tg proteome matched the protein alterations in AD
and another chronic, neurodegenerative disease, Parkinson’s disease (PD) [38]. We applied
a similar approach used with asymptomatic and late stage AD, wherein we analyzed
whether proteins found altered in the Tg hippocampal proteome were consistently altered
in AD or PD (Figure 6B). Interestingly, Tg animals and PD brains did not share consistently
altered homologous proteins, suggesting a tauopathy specific effect. Of the 19 significantly
altered proteins found in AD, 12 had homologs consistently changed in Tg animals (≈63%;
hypergeometric test * p < 0.05). Of these twelve proteins, 10 were rescued by 414: six unique
to Tg animals (GJA1, EEF1A1, IDH1, SGTB, PIN1, RHEB) and four proteins that are shared
across both late AD (human and Tg) datasets: PACSIN1, GJA1, VSNL1 and NDUFB5
(Figure 6C). These high-confidence candidate proteins represent targets associated with
cognitive decline in human AD with strong potential for drug-mediated rescue.
3. Discussion
Here, we uncover critical biological processes that contribute to neurotoxic processes
driving cognitive dysfunction in tauopathies using a broad kinase inhibitor, GSK2606414.
In doing so, we demonstrate the potential to mitigate the negative functional consequences
of tauopathy without altering tau hyper-phosphorylation. We treated early stage rTg4510
mice and firmly establish cognitive and molecular benefits of broad kinase inhibition.
With TMT quantitative proteomics, we identified biological processes that are affected
in transgenics and rescued by the compound. Finally, we cross-reference our findings to
human AD and PD brain proteomic data to narrow our results to high confidence unique
targets for future study. This approach revealed four distinct proteins associated with
cognitive decline in human tauopathy with strong therapeutic potential.
GSK2606414 ameliorates the molecular underpinnings of neurodegeneration including
neuronal loss, cognitive dysfunction and pathological protein accumulation in a variety
of disease models [11–16,18]. These studies established that the benefits of GSK2606414
were conferred by inhibition of its primary target, PERK, which was upregulated in disease.
While PERK is active in the rTg4510 tau transgenic model, this does not occur until after
6mo [11,26]. By treating rTg4510 mice from 4–5mo, a time point in which PERK levels
not activated, our study identified numerous PERK-independent pathways targeted by
GSK2606414 that elicited rescue from toxic outcomes in tauopathy. This has important
implications for data interpretation of this and previous studies.
Treatment with GSK2606414 broadly affected the hippocampal proteome of rTg4510
mice and only minimally affected non-transgenic controls. Many pathways critical for
neuronal health altered in human tauopathies were rescued in 414-treated tau transgenic
mice thereby supporting the growing evidence for multi-target engagement of GSK2606414.
Oral administration of 50–150 mg/kg GSK2606414 in mice results in a concentration
of the drug between 16.83–21.13 µM in the brain and 30.81–35.44 in blood plasma [12],
thereby putatively inhibiting over a dozen targets at these dosages (Table S1). Importantly,
chronic treatment with GSK2606414 reduces tau hyper-phosphorylation concomitant with
a disruption in pancreatic function and significant weight loss [12]. We did not identify
any change in tau hyperphosphorylation and no overt weight loss in GSK2606414-treated
animals, suggesting the duration of treatment may impact the broad drug-induced effect.
Many pathways affected by disease in this early stage of rTg4510 mice overlap with
altered pathways in AD brain such as glucose metabolism, immune response, synaptic
activity, the MAPK cascade and RNA metabolism, highlighting the similarity between this
model and human tauopathy [6–8,37]. Comparing our proteomic results with a study of
proteostatic dysfunction and protein aggregation in rTg4510 reveals no apparent correlation
of protein abundance between soluble and insoluble fractions [40]. These studies suggest
that our proteomic findings reflect alterations in expression and degradation rather than a
protein shift toward insolubility.
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Given the congruent pathway-level results between rTg4510 mice and human tauopa-
thy studies, we searched for novel candidate targets that were associated with rescued
cognitive function with GSK2606414 treatment. Overlapping the proteins consistent in
both AD datasets with data from transgenic mice revealed four novel, high-confidence
candidates that were associated with cognitive decline and drug-mediated multi-target
kinase inhibition: PACSIN1, GJA1, VSNL1 and NDUFB5. The neuronal protein PACSIN1
or protein kinase C and casein kinase substrate in neurons protein 1, participates in endo-
cytosis [41–43] and directly interacts with tubulin to promote microtubule formation [44].
There is evidence for direct tau-PACSIN1 binding, suggesting that this interaction im-
pinges upon tau’s capacity to bind microtubules [45] and represents a protein with a direct
link to tauopathy that could perturb cellular trafficking and tau/microtubule stability.
GJA1/connexin43 or gap junction alpha 1, functions to allow rapid inter-cellular communi-
cation of small molecules such as ions and neurotransmitters by establishing hemichannel
gap junctions between cells [46]. Many studies coupled GJA1 with the pathogenesis of neu-
rodegenerative diseases such as AD [47,48], most notably finding GJA1 incorporated into
amyloid plaques [49] and upregulated in AD models and human brain [6,50–52]. VSNL1
or visinin-like protein 1, is a neuronal calcium sensor (NCS) protein highly expressed in the
brain. As an NCS, VSNL1 responds to alterations in calcium concentration and coordinates
physiological processes such as cyclic nucleotide second messenger cascades and synaptic
receptor recycling [53–55]. While the full functional role of VSNL1 remains unclear, multi-
ple studies have implicated VSNL1 in progressing calcium and synaptic dysfunction in
AD [56], stroke [57] and schizophrenia [58]. Biomarker studies found increased VSNL1 in
CSF and plasma in early AD which correlated with cognitive dysfunction and neuronal
loss [59–62]. NDUFB5 or nicotinamide adenine dinucleotide dehydrogenase (ubiquinone)
1 beta subcomplex 5, is a nuclear-encoded mitochondrial protein which functions as part
of complex 1 of the electron transport chain. Many studies have shown NDUFB5 levels
is altered in disease, typically coupled with altered expression of other mitochondrial
respiratory proteins [63–66]. In the context of AD, NDUFB5 has been suggested as a hub
protein associated with disease pathogenesis based on co-expression analyses [67,68].
Taken together, our pre-clinical study contributes two major findings. First, we identify
discrete pathways contributing to cognitive changes in tauopathy and highlight four
unique proteins associated with cognitive rescue with strong therapeutic potential. Further
work investigating the novel targets identified in this study could discover better targets
amenable to pharmacological intervention and novel involvement in tauopathy. Second, we
demonstrate that broad, multi-family kinase inhibition can be a useful tool to mitigate the
molecular and functional decline in tauopathy. Since extensively multi-targeted approaches
meet safety challenges in the clinic, the development of compounds that selectively target
key kinase cascades at the same time could greatly benefit combinatorial therapies for the
treatment of tauopathy. Studies combining FDA-approved selective kinase inhibitors may
be beneficial toward advancing possible therapeutic strategies.
4. Materials and Methods
4.1. Study Design
The objective of this study was to determine the efficacy of broadly inhibiting kinase
activity for the treatment of early stage tauopathy. The rationale is that kinases are impli-
cated in the early pathogenesis and progression of tauopathies, such as AD, though our
understanding of the dysregulated kinase network in these diseases originates from studies
isolating the effect of one kinase or kinase family. Given the multi-factorial complexity of
these diseases, we investigated whether the considerable off-target effects of a pharmaco-
logical agent [69] could provide clinical benefit rather than act to confound experiments.
Therefore, we evaluated the effect of a compound originally developed as a selective in-
hibitor for PERK [10] and used in that context in a variety of disease models [11,12,16] but
which reportedly broadly targets kinases at low micromolar concentrations [10,17,18]. We
tested the outcomes of treating tau transgenic mice with this compound across a variety of
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functional, cognitive and molecular measures of tauopathy. We confirmed that the neuro-
protective effect of the compound is independent of PERK activity at this early age, though
older mice with PERK activity respond to the compound as previously reported. Lastly,
we investigated the protein changes underlying the cognitive dysfunction and subsequent
rescue at this age in tau transgenic mice. To control for transgene-specific effects in mice
which may not be recapitulated tauopathy in humans, we compared these results with two
separate measures of the AD proteome using different proteomic techniques to control for
potential systematic biases.
All experiments were designed with appropriate controls and based on previous
experiments to determine statistical power [22,27,70]. Animals were separated by genotype
and randomly assigned to treatment groups and experimental cohorts. Mice which did not
undergo full treatment course, such as those removed from analysis due to body weight
reduction past 80% of starting weight, were not analyzed for this study.
4.2. Animals
All animal studies were approved by the University of Kentucky’s Institutional Animal
Care and Use Committee (IACUC) and abided by that committee’s policies on animal care
and use in accordance with the Guide for the Care and Use of Laboratory Animals, the
Animal Welfare Regulations Title 9 Code of Federal Regulations Subchapter A, “Animal
Welfare,” Parts 1–3, and the Public Health Service Policy on Humane Care and Use of
Laboratory Animals. This University of Kentucky program and the facilities for animal
care and use are fully accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care International. The IACUC protocol number covering these
experiments was 2013-1145, approved 12 November 2013. The tau transgenic (rTg4510)
and parental mice were maintained and genotyped as described previously [20,27] and
were maintained on mixed FVB and 129S6 backgrounds. Mice of both sexes were used in
experiments unless otherwise stated.
4.3. Treatment with GSK2606414
GSK2606414 (GlaxoSmithKline, Philadelphia, PA, USA) was suspended in vehicle
(0.5% hydroxypropylmethyl cellulose + 0.1% Tween-80 in water at pH 4.0) as previously
described [12]. A total of 100 mg/kg GSK2606414 was delivered by oral gavage once
(100 mg/kg) or twice a day (50 mg/kg each separated by 10–12 h). Prior to treatment,
mice were handled twice daily to acclimate the animals for gavage. Unless otherwise
stated, four-month-old rTg4510 and non-transgenic mice were treated with GSK2606414 or
vehicle for 30–33 days ranging to 36 days to accommodate for environmental habituation
for behavioral and MRI assays. Daily weight records were kept to ensure accurate dosing
and to monitor potential GSK2606414-mediated weight loss [12]. Animals that lost more
than 20% of starting body weight were excluded from the study (Figure S4). No group
exhibited pronounced weight loss.
4.4. Statistical Analysis
Statistical analyses for all data apart from proteomics were performed using GraphPad
Prism 8 (Graph Pad Software, Inc. La Jolla, CA, USA). Proteomic analysis was completed
using R (3.6.2). Results are shown as the mean ± standard error or standard deviation as
described in each figure. Single-variate data were analyzed using unpaired Student’s t-test.
Multi-variate data were analyzed with one-way or two-way ANOVA where appropriate,
corrected for multiple comparisons with Tukey post-test analysis unless otherwise stated.
A value of p < 0.05 was considered statistically significant except for Reactome pathway
analyses which used an FDR-adjusted p value cutoff of 0.10.
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